faricimab: Clinical Trials

13 trials of faricimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 recruiting, 3 active not recruiting, 1 completed, 1 enrolling by invitation. 13 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 413Recruiting 6, Active not recruiting 3, Completed 1, Enrolling by invitation 1, Not yet recruiting 1, Unknown 1

Follow faricimab: new trials by email Literature Review of faricimab trials Research Report on faricimab

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
South Asian Patients With Diabetic Macular Oedema Treated With Faricimab Assessing the Efficacy, Durability, and Safety (SEAFAR Study)
Intravitreal anti-VEGF injection, Faricimab - Diabetic Macular Edema
Phase 4Not yet recruitingBirmingham and Midland Eye Centre Sandwell and west Birmingham NHS trust1202026-11-012026-08-07
A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome
Faricimab Injection [Vabysmo] - Presumed Ocular Histoplasmosis
Phase 4RecruitingCincinnati Eye Institute, Southwest Ohio252026-07-012026-07-10
Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration
Faricimab Injection [Vabysmo] - Macular Degeneration
Phase 4RecruitingJunyeop Lee642026-06-292026-07-27
Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material
Vabysmo 6 MG in 0.05 ML Injection - Macular Degeneration, Age Related
Phase 4RecruitingBiobizkaia Health Research Institute1002026-05-252026-05-28
Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration
Faricimab Injection [Vabysmo] - Macular Degeneration Choroidal Neovascularization
Phase 4RecruitingHospital Authority, Hong Kong402025-08-212025-10-01
Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)
Faricimab Injection [Vabysmo] - Polypoidal Choroidal Vasculopathy
Phase 4RecruitingAssociation for Innovation and Biomedical Research on Light and Image1202025-08-062026-02-06
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
Faricimab - Neovascular Age-related Macular Degeneration (nAMD)
Phase 4Active not recruitingHoffmann-La Roche2742025-03-142026-10-27
Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy
Faricimab Injection, sham treatment - Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
Phase 4Enrolling by invitationUniversity of Colorado, Denver1002024-07-122026-06-01
Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration
Aflibercept 40 MG/ML, Faricimab 120 MG/ML - Neovascular Age-related Macular Degeneration
Phase 4CompletedMedical University of Graz702023-07-042025-06-06
Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial
Faricimab - Diabetic Macular Edema
Phase 4Active not recruitingMcMaster University4462023-05-012026-04-17
Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals
Faricimab Injection - Wet Age-related Macular Degeneration
Phase 4RecruitingFaculty Hospital Kralovske Vinohrady1002023-03-312025-03-13
Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to Aflibercept
FARICIMAB 6 Mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [VABYSMO] - Diabetic Macular Edema
Phase 4UnknownVista Klinik302022-11-012022-11-09
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
Faricimab - Diabetic Macular Edema
Phase 4Active not recruitingGenentech, Inc.2182022-02-282026-08-25

Conditions studied

Macular Degeneration (2)  ·  Choroidal Neovascularization (1)  ·  Diabetic Retinopathy (1)  ·  Glycogen Storage Disease Type II (1)  ·  Polypoidal Choroidal Vasculopathy (1)

Sponsors

Association for Innovation and Biomedical Research on Light and Image (1)  ·  Biobizkaia Health Research Institute (1)  ·  Birmingham and Midland Eye Centre Sandwell and west Birmingham NHS trust (1)  ·  Cincinnati Eye Institute, Southwest Ohio (1)  ·  Faculty Hospital Kralovske Vinohrady (1)  ·  Genentech, Inc. (1)  ·  Hoffmann-La Roche (1)  ·  Hospital Authority, Hong Kong (1)  ·  Junyeop Lee (1)  ·  McMaster University (1)  ·  Medical University of Graz (1)  ·  University of Colorado, Denver (1)  ·  Vista Klinik (1)

Countries

United States (5)  ·  Spain (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Canada (2)  ·  Italy (2)  ·  South Korea (2)  ·  Austria (1)  ·  China (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Hong Kong (1)  ·  India (1)  ·  Kenya (1)

Top investigators

Andreas Wedrich, MD (1)  ·  Bushra Mushtaq, FRCS (1)  ·  Dr. Varun Chaudhary, MD, FRCS(C) (1)  ·  Junyeop Lee, PhD (1)  ·  Katja Hatz, MD (1)  ·  Martin Pencak, MD (1)

Results publications

PMID 42054086

NIH funding

2023 (1)